Menu
GeneBe

SPARC

secreted protein acidic and cysteine rich, the group of SPARC family

Basic information

Region (hg38): 5:151661095-151686975

Previous symbols: [ "ON" ]

Links

ENSG00000113140NCBI:6678OMIM:182120HGNC:11219Uniprot:P09486AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • osteogenesis imperfecta type 17 (Limited), mode of inheritance: AR
  • osteogenesis imperfecta type 17 (Strong), mode of inheritance: AR
  • osteogenesis imperfecta type 17 (Moderate), mode of inheritance: AR
  • osteogenesis imperfecta type 4 (Supportive), mode of inheritance: AD
  • osteogenesis imperfecta type 17 (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Keratoconus; Osteogenesis imperfecta, type XVIIAD/ARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingMusculoskeletal; Ophthalmologic21976959; 26027498
Evidence for pathogenicity of the described variants is unclear

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the SPARC gene.

  • not provided (152 variants)
  • Inborn genetic diseases (10 variants)
  • Osteogenesis imperfecta (8 variants)
  • Osteogenesis imperfecta type 17 (6 variants)
  • not specified (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the SPARC gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
38
clinvar
2
clinvar
41
missense
52
clinvar
2
clinvar
1
clinvar
55
nonsense
0
start loss
1
clinvar
1
frameshift
0
inframe indel
3
clinvar
3
splice donor/acceptor (+/-2bp)
1
clinvar
1
splice region
4
4
1
9
non coding
1
clinvar
28
clinvar
18
clinvar
47
Total 0 0 59 68 21

Variants in SPARC

This is a list of pathogenic ClinVar variants found in the SPARC region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
5-151662989-C-G Osteogenesis imperfecta Benign (May 21, 2022)1702066
5-151663423-A-T Likely benign (May 06, 2019)1317768
5-151663455-CTA-C Osteogenesis imperfecta type 17 Likely benign (Apr 01, 2024)2920766
5-151663516-G-C Osteogenesis imperfecta type 17 Uncertain significance (Jun 28, 2018)1032875
5-151663524-G-A SPARC-related disorder Likely benign (Apr 05, 2022)3031376
5-151663542-G-C Benign (Aug 25, 2018)1272922
5-151663582-G-C Uncertain significance (May 18, 2022)1959323
5-151663584-T-A Uncertain significance (May 11, 2023)2779900
5-151663592-G-A Likely benign (Nov 13, 2023)733843
5-151663652-G-A Benign (Aug 25, 2018)1291605
5-151663739-C-T Likely benign (Sep 15, 2019)1316474
5-151663981-C-G Likely benign (Aug 30, 2018)1316853
5-151664078-G-C Likely benign (Sep 23, 2022)1969548
5-151664080-C-T Likely benign (Mar 21, 2023)3014968
5-151664097-G-A SPARC-related disorder Likely benign (Apr 05, 2022)3054232
5-151664100-G-A Likely benign (Aug 04, 2023)1598484
5-151664109-G-A Osteogenesis imperfecta • SPARC-related disorder Benign/Likely benign (Jan 25, 2024)733348
5-151664126-C-T Uncertain significance (Jul 21, 2022)1989409
5-151664127-G-A Likely benign (Dec 06, 2022)2788428
5-151664133-C-T Likely benign (Feb 03, 2023)2867830
5-151664144-C-T Uncertain significance (Sep 19, 2021)1346295
5-151664148-G-C Inborn genetic diseases Uncertain significance (Feb 26, 2024)2156503
5-151664154-G-T SPARC-related disorder Likely benign (Sep 21, 2023)747118
5-151664159-C-T Uncertain significance (Jul 05, 2022)1508224
5-151664160-G-A Benign/Likely benign (Jan 01, 2024)716022

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
SPARCprotein_codingprotein_codingENST00000231061 926070
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.8910.108125740061257460.0000239
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.101391810.7700.00001032017
Missense in Polyphen6080.7580.74296865
Synonymous0.03797474.40.9940.00000470551
Loss of Function3.24216.00.1256.78e-7192

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00002900.0000290
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.00002640.0000264
Middle Eastern0.000.00
South Asian0.00006530.0000653
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Appears to regulate cell growth through interactions with the extracellular matrix and cytokines. Binds calcium and copper, several types of collagen, albumin, thrombospondin, PDGF and cell membranes. There are two calcium binding sites; an acidic domain that binds 5 to 8 Ca(2+) with a low affinity and an EF-hand loop that binds a Ca(2+) ion with a high affinity.;
Disease
DISEASE: Osteogenesis imperfecta 17 (OI17) [MIM:616507]: An autosomal recessive form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. {ECO:0000269|PubMed:26027498}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
miR-targeted genes in muscle cell - TarBase;miR-509-3p alteration of YAP1-ECM axis;EMT transition in Colorectal Cancer;Senescence and Autophagy in Cancer;Vesicle-mediated transport;Extracellular matrix organization;Platelet degranulation ;Response to elevated platelet cytosolic Ca2+;Platelet activation, signaling and aggregation;TGF_beta_Receptor;Hemostasis;ECM proteoglycans;Scavenging by Class H Receptors;Binding and Uptake of Ligands by Scavenger Receptors (Consensus)

Recessive Scores

pRec
0.765

Intolerance Scores

loftool
0.256
rvis_EVS
0.31
rvis_percentile_EVS
72.38

Haploinsufficiency Scores

pHI
0.983
hipred
Y
hipred_score
0.825
ghis
0.563

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.855

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Sparc
Phenotype
craniofacial phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); pigmentation phenotype; neoplasm; limbs/digits/tail phenotype; vision/eye phenotype; immune system phenotype; skeleton phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype;

Zebrafish Information Network

Gene name
sparc
Affected structure
blood cell
Phenotype tag
abnormal
Phenotype quality
decreased amount

Gene ontology

Biological process
ossification;negative regulation of endothelial cell proliferation;platelet degranulation;receptor-mediated endocytosis;heart development;response to gravity;response to lead ion;positive regulation of endothelial cell migration;negative regulation of angiogenesis;regulation of cell morphogenesis;extracellular matrix organization;lung development;response to lipopolysaccharide;response to L-ascorbic acid;response to cytokine;wound healing;response to peptide hormone;pigmentation;response to ethanol;response to cadmium ion;inner ear development;regulation of synapse organization;response to glucocorticoid;response to cAMP;response to calcium ion;bone development;cellular response to growth factor stimulus
Cellular component
extracellular region;basement membrane;extracellular space;cytoplasm;mitochondrion;plasma membrane;cell surface;nuclear matrix;platelet alpha granule;platelet alpha granule membrane;platelet alpha granule lumen;collagen-containing extracellular matrix;endocytic vesicle lumen;glutamatergic synapse
Molecular function
extracellular matrix structural constituent;calcium ion binding;protein binding;collagen binding;extracellular matrix binding